CN114728036A - 新治疗用途 - Google Patents

新治疗用途 Download PDF

Info

Publication number
CN114728036A
CN114728036A CN201980101223.8A CN201980101223A CN114728036A CN 114728036 A CN114728036 A CN 114728036A CN 201980101223 A CN201980101223 A CN 201980101223A CN 114728036 A CN114728036 A CN 114728036A
Authority
CN
China
Prior art keywords
pol
cells
inhibitors
compound
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980101223.8A
Other languages
English (en)
Chinese (zh)
Inventor
H·M·R·罗宾逊
G·C·M·史密斯
C·J·洛德
D·扎图阿努
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atios Pharmaceutical Co ltd
Original Assignee
Atios Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atios Pharmaceutical Co ltd filed Critical Atios Pharmaceutical Co ltd
Publication of CN114728036A publication Critical patent/CN114728036A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980101223.8A 2019-08-09 2019-08-09 新治疗用途 Pending CN114728036A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2019/052243 WO2021028644A1 (en) 2019-08-09 2019-08-09 Novel therapeutic use

Publications (1)

Publication Number Publication Date
CN114728036A true CN114728036A (zh) 2022-07-08

Family

ID=74570294

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980101223.8A Pending CN114728036A (zh) 2019-08-09 2019-08-09 新治疗用途

Country Status (6)

Country Link
US (1) US20220387544A1 (https=)
EP (1) EP4010002A1 (https=)
JP (2) JP2023501038A (https=)
CN (1) CN114728036A (https=)
CA (1) CA3149112A1 (https=)
WO (1) WO2021028644A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358886B2 (en) * 2019-08-09 2025-07-15 Artios Pharma Limited Heterocyclic compounds for use in the treatment of cancer
EP4455129A4 (en) * 2021-12-30 2025-05-07 Shanghai Apeiron Therapeutics Company Limited Dna polymerase theta inhibitor and use thereof
TW202332442A (zh) 2022-01-31 2023-08-16 瑞士商瑞森製藥公司 ＰＯＬθ抑制劑
WO2024197653A1 (en) * 2023-03-29 2024-10-03 Suzhou Eoc Medical Research Co., Ltd. Heterocyclic compounds and uses thereof
WO2025011603A1 (zh) * 2023-07-12 2025-01-16 南京再明医药有限公司 一种化合物用于预防或治疗53BP1/Shieldin复合物缺陷的癌症的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013133876A1 (en) * 2011-12-07 2013-09-12 The Regents Of The University Of California Biomarkers for prediction of response to parp inhibition in breast cancer
WO2017070198A1 (en) * 2015-10-19 2017-04-27 Dana-Farber Cancer Institute, Inc. Polymerase q as a target in hr-deficient cancers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358886B2 (en) * 2019-08-09 2025-07-15 Artios Pharma Limited Heterocyclic compounds for use in the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013133876A1 (en) * 2011-12-07 2013-09-12 The Regents Of The University Of California Biomarkers for prediction of response to parp inhibition in breast cancer
WO2017070198A1 (en) * 2015-10-19 2017-04-27 Dana-Farber Cancer Institute, Inc. Polymerase q as a target in hr-deficient cancers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GEOFF S. HIGGINS等: "Beyond PARP—POLu as an anticancer target", SCIENCE, vol. 359, 16 March 2018 (2018-03-16), pages 1217 - 1218, XP055529688, DOI: 10.1126/science.aar5149 *
RAJAT GUPTA等: "DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity", CELL, vol. 173, no. 4, 3 May 2018 (2018-05-03), pages 972, XP055530007, DOI: 10.1016/j.cell.2018.03.050 *
SYLVIE M. NOORDERMEER等: "The shieldin complex mediates 53BP1-dependent DNA repair", NATURE, vol. 560, 2 August 2018 (2018-08-02), pages 117 - 141 *

Also Published As

Publication number Publication date
JP2023501038A (ja) 2023-01-18
WO2021028644A1 (en) 2021-02-18
CA3149112A1 (en) 2021-02-18
US20220387544A1 (en) 2022-12-08
EP4010002A1 (en) 2022-06-15
JP2024059632A (ja) 2024-05-01

Similar Documents

Publication Publication Date Title
EP4081305B1 (en) Diacylglycerol kinase modulating compounds
AU2019416117B2 (en) CSF1R inhibitors for use in treating cancer
EP4010329B1 (en) Deuterated compounds for use in the treatment of cancer
CN114728036A (zh) 新治疗用途
US20240166623A1 (en) Novel process
KR20190092478A (ko) 화학요법 레지멘 동안의 면역 반응의 보존
EP4359389A1 (en) Diacylglyercol kinase modulating compounds
US20230046340A1 (en) Diacylglyercol kinase modulating compounds
KR20180013850A (ko) 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도
WO2022271684A1 (en) Diacylglyercol kinase modulating compounds
KR20240122783A (ko) Fgfr 저해제 및 kras 저해제를 포함하는 병용 요법
TW202334150A (zh) 新穎化合物
US20210275518A1 (en) Methods of using rebastinib in the treatment of disorders
CN118632696A (zh) 包含fgfr抑制剂和kras抑制剂的组合疗法
CN112294814A (zh) 用于治疗胶质母细胞瘤的喹啉衍生物
HK40076656A (en) Deuterated compounds for use in the treatment of cancer
HK40076656B (en) Deuterated compounds for use in the treatment of cancer
HK40082507B (en) Diacylglycerol kinase modulating compounds
HK40082507A (en) Diacylglycerol kinase modulating compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220708